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Backgrounds: Epithelial cell apoptosis plays an important role in the pathogenesis of idiopathic
interstitial pneumonia (IIP).
Methods: Serum levels of caspase-cleaved cytokeratin-18 (M30) were measured in 55 patients
with IIP and 34 healthy controls using enzyme-linked immunosorbent assays. The IIP cases
included usual interstitial pneumonia (UIP; n Z 30), nonspecific interstitial pneumonia (NSIP;
n Z 15), and cryptogenic organizing pneumonia (COP; n Z 10). The radiological scoring was
performed based on high-resolution computed tomography (HRCT) findings.
Results: Patients with IIP had higher serum M30 levels than did the control group (178.6  91.5
vs. 113.7  46.8 U/L, p < 0.05). Among IIP patients, COP patients had higher serum M30 levels
than did UIP or NSIP patients (264.9  132.7, 139.2  49.7, and 201.2  81.1 U/L, respectively;
COP vs. UIP, p < 0.01). Serum M30 levels were negatively correlated with forced vital capacity
(FVC; rs Z 0.31), percent-predicted FVC (FVC%; rs Z 0.38), and percent-predicted forced
expiratory volume in 1 s (FEV1%; rsZ 0.36). Serum M30 levels were correlated with radiolog-
ical ground-glass opacity scores (rs Z 0.61).
Conclusion: The epithelial apoptosis marker serum level was correlated with IIP clinical status
and is a potential marker to assess IIP.
ª 2010 Elsevier Ltd. All rights reserved.1 219 5121; fax: þ82 31 219 5124.
(K.J. Park).
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Although significant progress has been made in under-
standing idiopathic interstitial pneumonia (IIP), especially
with regard to the clinical and pathological aspects, the
fundamental pathophysiological mechanisms of the disease
are still largely unknown.
Numerous pathways and mediators participate in the
pathogenesis of IIP, and apoptosis has been proposed to
play a significant role in its development, as in many other
diseases.1e5
Apoptosis can be viewed in two opposite ways in the
development and progress of IIP. First, epithelial cells
suffer from enhanced apoptosis, and repetitive injuries
with disruptions in repairs perpetuate and aggravate this
response.2,4,6 By contrast, interstitial fibroblasts show
resistance to apoptosis, resulting in the prolongation of
survival and proliferation.7e9 These two aspects of
apoptosis are coordinated and eventually lead to irrevers-
ible fibrosis and honeycombing, which is the hallmark of the
final manifestation of the disease process.
Persistently enhanced apoptosis and impaired re-
epithelialization provide a favourable environment for
fibroblast proliferation.10,11 Also, an epi-
thelialemesenchymal cell interaction may be governing
disease progression.12,13
Enhanced epithelial cell apoptosis has been demon-
strated using many cellular and animal model studies, with
corresponding alterations in apoptosis-related mediators,
and it has also been documented in the human tissues of
idiopathic pulmonary fibrosis (IPF).2,6,14
Among IIP subtypes, cryptogenic organizing pneumonia
(COP) also shows upregulation of pro-apoptotic mediators
such as sFas in the tissues and bronchoalveolar lavage fluid,
and it is more prominent than in usual interstitial pneu-
monia (UIP).15
Many blood markers have been used to assess IIP with
varying degrees of success.16e20 A specific epithelial
apoptosis marker, developed by measuring the caspase-
cleaved cytokeratin-18 fragments, has been introduced and
utilized for the evaluation of apoptosis in many
diseases.21,22
We assessed the clinical significance and utility of this
marker in patients with IIP by measuring the levels of
cleaved cytokeratin-18 shed into peripheral blood.
Methods
Subjects
A total of 55 patients with IIP were enrolled from January
2005 to March 2009. The IIP diagnosis was made according
to the American Thoracic Society (ATS)/European Respira-
tory Society (ERS) criteria.23 Among IIP subtypes, UIP,
nonspecific interstitial pneumonia (NSIP), and COP were
included in this study due to the rarity of the other
subtypes. Among the 30 patients with UIP, 24 cases were
pathologically confirmed by surgical biopsy. The remaining
six were diagnosed based on the clinical and radiological
background: insidious onset of otherwise unexplained
dyspnea on exertion; persistent crackles noted byauscultation; pulmonary fibrosis indicated by HRCT find-
ings, consisting of a honeycomb pattern with basal and
peripheral reticular opacities and traction bronchiectasis,
in the absence of peribronchovascular nodules, micro-
nodules, isolated cysts, and consolidation; abnormal
pulmonary function test results, including evidence of lung
restriction, hypoxemia, and decreased carbon monoxide
diffusing capacity (DLCO), in the absence of other causes of
pulmonary fibrosis; transbronchial biopsy showing no
features incompatible with a diagnosis of IPF (this was not
mandatory); age 50 years; and duration of illness >3
months. In all cases, the extent of ground-glass opacity
(GGO) was less than the extent of the honeycomb lung. All
cases of NSIP and COP were histopathologically confirmed
in surgical lung biopsy specimens, and the patients were
confirmed to have had no exposure or concomitant systemic
disease that might have been contributory.
Patients who had smoked cigarettes regularly within the
previous year were designated as current smokers; those
who had not smoked cigarettes in the previous year, but
had smoked in the past were designated as former smokers;
the other patients were non-smokers.
Only patients in a stable status were included, and
patients with acute exacerbation, acute infections, or
inflammatory conditions were excluded. Patients with
fibrotic diseases in the lungs or any organs, underlying
collagen vascular disease, recent major surgery, or malig-
nancy in any organ were excluded from the study. None of
the patients had received oral or inhaled corticosteroids, or
other immunosuppressants, at the time of sample collec-
tion. To eliminate significant chronic obstructive airway
diseases, we excluded cases with forced expiratory volume
in 1 s/forced vital capacity (FEV1/FVC) <0.7 and percent-
predicted FEV1 (FEV1%) <80%.
Pulmonary function test
The pulmonary function test (PFT) was conducted accord-
ing to the American Thoracic Society (ATS) guidelines.24
Spirometry and body plethysmography were performed
using an Elite Dx (Medical Graphic Corp., St. Paul, MN, USA).
The following dynamic and static lung volumes were
assessed: FEV1, FVC, FEV1/FVC ratio, total lung capacity
(TLC), and residual volume (RV). Carbon monoxide diffusing
capacity (DLCO) was measured by the single-breath method.
Individual results were compared with the predicted
values.
Control recruitment
A control group was recruited during the last 6 months of
the study. We screened 50 age- and gender-matched
subjects who had received general health examinations and
agreed to donate blood samples. We interviewed the
subjects and reviewed the results of their examinations,
which included a medical history, physical examination,
and various tests. The tests consisted of basic laboratory
tests, blood hormone and tumour markers, chest roent-
genogram, electrocardiography, abdominal ultrasound,
spirometry, gastric endoscopy, and in some cases, a bowel
study, computed tomography, and positron-emission
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significant test abnormalities requiring further evaluation,
were excluded. We included subjects with normal FEV1/
FVC values (>70%) and normal percent-predicted FVC (FVC
%) (>80%) according to age and gender. The DLCO was not
measured in the control group. After the screening process,
34 subjects qualified as appropriate controls.
Written consent was provided by each patient and
control, and the study was approved by the Institutional
Review Board of the Hospital.
High-resolution computed tomography (HRCT)
scoring
The HRCT scoring for IIP was conducted with a slight
modification of a published protocol.25 Briefly, an HRCTwas
performed using a 16-detector-row CT scanner (Brilliance
16; Philips Medical Systems, Best, the Netherlands or
Sensation 16; Siemens, Erlangen, Germany). The CT scans
were obtained with the patients in a supine position and in
maximum inspiration. Additional slices in prone position
were acquired in selected cases to detect gravity-induced
subpleural opacity. The HRCT scan were obtained from the
lung apices through the bases with a slice thickness of 1 mm
(Sensation 16) or 1.2 mm (Brilliance 16) and interslice gaps
of 10 mm (effective 200 mAs, 120 kVp). Images were viewed
on standard lung windows (level 600 to 700 HU; width
1000e1500 HU) and mediastinal windows (level 20 HU;
width 400 HU). Images were reconstructed using a high
spatial frequency algorithm. CT scans were reviewed
independently by two experienced thoracic radiologists
without knowledge of the clinical, physiological, or patho-
logical parameters. Five images were taken: at the level of
the aortic arch, the midpoint between the aortic arch and
the carina, the carina, the midpoint between the carina
and 1 cm above the diaphragm, and 1 cm above the dia-
phragm. Both sides of the five levels were scored on a scale
of 0e5 for both alveolar (GGO score) and interstitial
(reticular score) abnormalities. When accompanied by
HRCT findings of fibrosis, GGO may indicate fibrosis, rather
than inflammation. Accordingly, to minimize misinterpre-
tation, the radiologists carefully reviewed the HRCT find-
ings in cases exhibiting GGO. The scores for each level were
averaged for data analysis. In cases of disagreement,
consensus was reached by discussion.
Measurement of epithelial apoptosis marker serum
levels
Sera were collected from patients with IIP and the
controls, and were stored at 70 C until analysis. To
evaluate epithelial apoptosis, we measured caspase-
cleaved cytokeratin-18 levels using the M30-Apoptosense
enzyme-linked immunosorbent assay (ELISA) kit (PEVIVA
AB, Bromma, Sweden). Cytokeratin-18 is a type I inter-
mediate filament protein and the major component of
epithelial cells, but it is not contained in other cell types
such as mesenchymal or bone marrow-derived cells. The
M30-ELISA assay is based on the epitope-specific M30
antibody, which only recognizes soluble cytokeratin-18
fragments cleaved at Asp396 (M30 antigen) by caspases.M30 antigen levels are expressed as units per litre.
According to the manufacturer, 1 unit (U) corresponds to
1.24 pmol of a synthesized peptide containing the M30
recognition motif.Statistical analysis
The data were analyzed using SPSS for Windows (version
12; SPSS, Chicago, IL, USA). Continuous variables are pre-
sented as means  SD. Categorical variables are expressed
as absolute counts or percentages, and were compared
using the chi-square and Fisher’s exact test, as appro-
priate. The ManneWhitney U test was used to compare M30
levels and other parameters between the IIP patient group
and the control group. To compare M30 levels and other
parameters among IIP subtypes, the KruskaleWallis test
was used. When necessary, Dunn’s nonparametric multiple-
comparison procedure was applied. Spearman’s rank
coefficient correlation was used to analyze correlations
between M30 levels and PFT data and radiologic scores. A
value of p < 0.05 was considered to indicate statistical
significance.Results
Fifty-five patients with IIP were included in this study. The
mean age of the patients was 60.3  12.7 years, and 36
were male. The healthy controls were 34 individuals with
a mean age of 57.1  7.8 years, and 13 were female. The
demographic characteristics, pulmonary function data, and
radiological scoring data are shown in Table 1. Smoking
status was the same between the IIP group and the control
group, and the M30 level did not differ significantly
according to the smoking status.
Patients with IIP had higher serum M30 levels than did
the control group (178.6  91.5 vs. 113.7  46.8 U/L,
p < 0.05). Among IIP patients, COP patients had signifi-
cantly higher serum M30 levels than did UIP patients
(264.9  132.7 vs. 139.2  49.7 U/L; p < 0.01). The mean
M30 level in UIP patients tended to be higher than that in
the control group (p Z 0.057). The mean M30 level in NSIP
patients (201.2  81.1 U/L) was significantly higher than
that in UIP patients (p < 0.05) and tended to be lower,
although not significantly lower, than that in COP patients
(Fig. 1).
Serum M30 levels were negatively correlated with FVC
(rs Z 0.31, p < 0.05), FVC% (rs Z 0.38, p < 0.01), and
FEV1% (rs Z 0.36, p < 0.05), and tended to be negatively
correlated with FEV1 (rs Z 0.28, p Z 0.051) (Fig. 2).
Serum M30 levels were only marginally correlated with TLC
(rsZ 0.29, pZ 0.10) and were not correlated with DLCO.
Serum M30 levels were significantly correlated with GGO
scores (rsZ 0.61, p < 0.0001) but not with reticular scores
(Fig. 3).
In the subgroup analysis, COP patients had a significantly
greater correlation of the M30 level with the GGO score
(rsZ 0.77, p < 0.001), compared with the other subgroups.
Although statistical significance was not reached owing to
the small numbers of patients, the M30 level also showed
the greatest correlation with PFT parameters in COP
Table 1 Study population characteristics.
UIP NSIP COP Controls
Subjects, n 30 15 10 34
Age, yrs 66.8  8.3 50.1  11.5 55.9  14.1 57.1  7.8
Male, n (%) 25 (83) 6 (40) 5 (50) 21 (62)
Smoking status, n (%)
Current 6 (20) 2 (13) 1 (10) 5 (15)
Former 10 (33) 3 (20) 3 (30) 9 (26)
Never 14 (47) 10 (67) 6 (60) 20 (59)
PFT
FVC (L) 2.51  0.91 2.0  0.53 2.47  0.75 3.54  0.74##
FVC % predicted 77.2  16.3 63.6  12.2* 74.4  24.4 99.5  13.4##
FEV1 (L) 2.08  0.68 1.71  0.43 1.96  0.56 2.97  0.57##
FEV1% predicted 84.8  15.9 67.4  11.7* 77.2  25.0 105.7  13.3##
FEV1/FVC 84.7  7.8 85.8  4.8 79.9  6.1 84.3  5.2
DLCO (mL/min/mmHg) 11.8  3.9 10.8  2.8 11.8  5.4
DLCO% predicted 50.7  12.4 52.4  18.3 53.5  25.5
TLC (L) 3.86  1.34 3.10  0.90 3.92  1.21
TLC% predicted 73.5  14.8 61.5  12.2* 75.0  19.5
HRCT score
GGO score 1.2  0.5 1.7  0.6** 1.8  0.7**
Reticular score 1.5  0.6# 0.9  0.4 0.9  0.3
Data are presented as mean  SD or n (%). UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; COP: cryptogenic
organizing pneumonia; PFT: pulmonary function test; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing
capacity for carbon monoxide; TLC: total lung capacity; HRCT: high-resolution computed tomography; GGO: ground-glass opacity, *less
than UIP, p < 0.05, **more than UIP, p < 0.05, #more than NSIP and COP, p < 0.05, ##more than all other groups, p < 0.01.
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p Z 0.10), compared with the other IIP subtypes.
Discussion
We have found increased levels of an epithelial cell
apoptosis marker, which were reflected in the serum of IIP
patients. Among the three IIP subtypes studied, patient
with COP showed higher levels than those with UIP. Also,Figure 1 The serum caspase-cleaved cytokeratin-18 frag-
ment (M30) levels in idiopathic interstitial pneumonia patients
and controls. UIP: usual interstitial pneumonia; NSIP: nonspe-
cific interstitial pneumonia; COP: cryptogenic organizing
pneumonia.epithelial apoptosis marker serum levels correlated with
the pulmonary function parameters and the radiological
grading scores.
The GGO on HRCT scans mainly represents an inflam-
matory reaction during IIP development. It is pathologically
designated as active alveolitis, denoting the presence of
cells or fluid filling the alveolar spaces.26 There was
significant correlation between the epithelial apoptosis
marker and GGO, both of which occur in relatively early
stages of IIP pathogenesis.1 The role of inflammation as
a major pathogenetic contributor has been disputed,27 and
a direct causal relationship between apoptosis and inflam-
mation has not been demonstrated, although their inter-
relationship has been indirectly documented by previous
reports. An important degree of crosstalk between Fas-
dependent apoptosis pathways and pro-inflammatory
pathways has been shown.28e30 Furthermore, TGF-b has
been reported to modulate alveolar inflammation and
apoptosis.31 However, the present study does not present
a pathobiological background for the correlation. We only
measured an end-product of epithelial apoptosis, and we
did not conduct a mechanistic study to elucidate their
relationship. It is possible that apoptosis is a mere indirect
phenomenon secondary to the inflammation.
The correlation of the epithelial apoptosis marker with
FVC and FVC% can be reasonably explained by the alveolar
inflammation and flooding that accompanies epithelial
apoptosis. The epithelial apoptosis marker was also corre-
lated with FEV1%. This was not anticipated in the results,
given that IIP is mainly a restrictive pulmonary disorder.
This relationship may be explained by the fact that
apoptosis occurs in both bronchiolar and alveolar epithelial
Figure 2 Correlation between caspase-cleaved cytokeratin-18 fragment (M30) levels and (A) forced vital capacity (FVC), (B)
percent-predicted FVC (FVC%), (C) forced expiratory volume in 1 s (FEV1), and (D) percent-predicted FEV1 (FEV1%) in patients with
idiopathic interstitial pneumonia.
1726 W.Y. Chung et al.cells.32 Bronchiolar apoptosis/inflammation may have
contributed to the obstructive impairment in pulmonary
function. Also, PFT may show an obstructive pattern in
patients with COP, and may have contributed to M30’s
correlation with FEV1 as shown in the results.
The specific evaluation of epithelial apoptosis utilized in
our study may be more useful than an overall apoptosis
assessment in that the latter does not specifically reflect
individual cell types, so the results may be attenuated.
A caution is required in the interpretation and clinical
utility of the present study results. Epithelial cell apoptosis
is important, but it is only part of the entire pathogenetic
process in IIP. In the advanced stages of IIP, especially in
IPF, the main process and major determinant of lung
function is progressive fibrosis, not inflammation or
apoptosis. Epithelial apoptosis can only partly account for
the disease status, and as the stage progresses, its utility
may be lessened. The weak correlation between M30 levelsFigure 3 Correlation between caspase-cleaved cytokeratin-
18 fragment (M30) levels and HRCT ground-glass opacity (GGO)
scores in patients with idiopathic interstitial pneumonia.and PFT parameters may have resulted from this caveat as
well as from the inherent limitation of reflecting organ
status from an indirect measurement of blood levels. In this
regard, the validity of the epithelial apoptosis marker
should be confined to mild and moderately advanced cases.
A significant correlation may have been obtained because
the majority of our patients were in those categories. The
lack of a correlation between M30 and DLCO, an important
pulmonary functional parameter in interstitial lung
diseases, may reflect this limitation.
In the comparison among IIP subtypes, patients with COP
showed higher M30 levels than did other patients, espe-
cially those with UIP. These results concur with a previous
tissue study that showed higher apoptotic activity with
corresponding changes in apoptosis-regulatory mediators in
COP than in UIP.33 In the comparison between UIP and NSIP,
NSIP M30 levels were higher than UIP. However, a previous
tissue study found increased epithelial apoptosis in UIP
compared with NSIP cases.34 This discrepancy may be
attributed to the status of the study population. In the
present study, NSIP patients were relatively severe cases
compared with UIP patients, considering the PFT data. The
evaluation of epithelial apoptosis may not have discrimi-
nating power between UIP and NSIP, but may only reflect
the severity of pulmonary pathology that both entities
share. Also, the subgroup analysis indicated considerable
overlap among the groups, despite the statistically signifi-
cant differences. Therefore, M30 showed limited utility in
the diagnosis or differentiation of patients with IIP. The
significance of the M30 level should be limited to its clinical
utility as a surrogate marker in the assessment of IIP
patients, given its significant correlations with PFT param-
eters and radiologic findings.
Weacknowledge several limitations inour study. First, the
patients’ pulmonary function data were limited. A detailed
Epithelial apoptosis in idiopathic interstitial pneumonia 1727functional assessment of the patients such as the 6-min
walking test and cardiopulmonary exercise tests could not be
analyzed due to lack of data. Second, the serum levels of the
epithelial apoptosis marker were not compared with
apoptosis tissue levels, which would have been more infor-
mative, although small pieces of lung tissue might not
represent apoptotic activity in the whole lung. Third, blood
levels of the apoptosis marker were not serially followed up,
which would have been meaningful, especially in the case of
more treatable entities such as NSIP or COP. Lastly, we
cannot be certain that other pro-apoptotic events were
completely ruled out, despite our diligent efforts to elimi-
nate those conditions. In particular, chronic obstructive
pulmonary disease (COPD) might have co-existed in the
patients with IIP. We included cases with a mild obstructive
pattern of pulmonary function, in order to prevent the
exclusion of data from some IIP patients; this might have had
an effect on the results. In addition, smoking status was not
well matched among the subgroups, and this might have
biased the results.
In conclusion, we found that the serum level measure-
ment of the epithelial apoptosis marker correlated with IIP
clinical status, and its potential utility as a clinical marker
suggests its use in the evaluation of IIP. These results
warrant further study in more cases in the future.
Conflict of interest
The authors have no conflict of interest financial or other-
wise regarding this manuscript.
References
1. Kuwano K. Involvement of epithelial cell apoptosis in intersti-
tial lung diseases. Intern Med 2008;47:345e53.
2. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N,
Nakanishi Y, et al. P21Waf1/Cip1/Sdi1 and p53 expression in
association with DNA strand breaks in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 1996;154:477e83.
3. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR,
Capelozzi VL. Evidence of type II pneumocyte apoptosis in the
pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual
interstitial pneumonia (UIP). J Clin Pathol 2001;54:132e8.
4. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abroga-
tion of bleomycin-induced epithelial apoptosis and lung fibrosis
by captopril or by a caspase inhibitor. Am J Physiol Lung Cell
Mol Physiol 2000;279:L143eL151.
5. Selman M, Pardo A. Role of epithelial cells in idiopathic
pulmonary fibrosis: from innocent targets to serial killers. Proc
Am Thorac Soc 2006;3:364e72.
6. Plataki M, Koutsopoulos AV, Darivianaki K, Delides G,
Siafakas NM, Bouros D. Expression of apoptotic and anti-
apoptotic markers in epithelial cells in idiopathic pulmonary
fibrosis. Chest 2005;127:266e74.
7. Buhling F, Wille A, Rocken C, Wiesner O, Baier A, Meinecke I,
et al. Altered expression of membrane-bound and soluble
CD95/Fas contributes to the resistance of fibrotic lung fibro-
blasts to FasL induced apoptosis. Respir Res 2005;6:37.
8. Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE,
Zhang H, et al. Activation of the pro-survival phosphatidyli-
nositol 3-kinase/AKT pathway by transforming growth factor-
beta1 in mesenchymal cells is mediated by p38 MAPK-depen-
dent induction of an autocrine growth factor. J Biol Chem
2004;279:1359e67.9. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in
idiopathic pulmonary fibrosis. Proc AmThorac Soc 2006;3:350e6.
10. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O,
Masugi Y. The role of intraalveolar fibrosis in the process of
pulmonary structural remodeling in patients with diffuse
alveolar damage. Am J Pathol 1987;126:171e82.
11. Adamson IY, Young L, Bowden DH. Relationship of alveolar
epithelial injury and repair to the induction of pulmonary
fibrosis. Am J Pathol 1988;130:377e83.
12. Selman M, Pardo A. The epithelial/fibroblastic pathway in the
pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell
Mol Biol 2003;29:S93eS97.
13. Waghray M, Cui Z, Horowitz JC, Subramanian IM, Martinez FJ,
Toews GB, et al. Hydrogen peroxide is a diffusible paracrine
signal for the induction of epithelial cell death by activated
myofibroblasts. FASEB J 2005;19:854e6.
14. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N.
Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-
induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol
1997;16:91e101.
15. Kuwano K, Kawasaki M, Maeyama T, Hagimoto N, Nakamura N,
Shirakawa K, et al. Soluble form of fas and fas ligand in BAL
fluid from patients with pulmonary fibrosis and bronchiolitis
obliterans organizing pneumonia. Chest 2000;118:451e8.
16. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR,
et al. Serum CC-chemokine ligand 18 concentration predicts
outcome in idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med 2009;179:717e23.
17. Greene KE, King Jr TE, Kuroki Y, Bucher-Bartelson B,
Hunninghake GW, Newman LS, et al. Serum surfactant
proteins-A and -D as biomarkers in idiopathic pulmonary
fibrosis. Eur Respir J 2002;19:439e46.
18. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A,
Schwarz MI, et al. Serum surfactant protein-A is a strong
predictor of early mortality in idiopathic pulmonary fibrosis.
Chest 2009;135:1557e63.
19. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al.
Circulating fibrocytes are an indicator of poor prognosis in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;
179:588e94.
20. Ide M, Ishii H, Mukae H, Iwata A, Sakamoto N, Kadota J, et al.
High serum levels of thrombospondin-1 in patients with idio-
pathic interstitial pneumonia. Respir Med 2008;102:1625e30.
21. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S.
Measurement of an apoptotic product in the sera of breast
cancer patients. Eur J Cancer 2003;39:769e74.
22. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J,
Steiner G, et al. Differentiation between cell death modes
using measurements of different soluble forms of extracellular
cytokeratin 18. Cancer Res 2004;64:1751e6.
23. ERS Executive Committee. American Thoracic Society/Eur-
opean Respiratory Society International Multidisciplinary
Consensus Classification of the Idiopathic Interstitial Pneumo-
nias. This joint statement of the American Thoracic Society
(ATS), and the European Respiratory Society (ERS) was adopted
by the ATS board of directors, June 2001. Am J Respir Crit Care
Med 2002;165:277e304.
24. Standardization of spirometrye1987 update. Statement of the
American thoracic Society. Am Rev Respir Dis 1987;136:
1285e98.
25. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH,
Spizarny DL, et al. Thin-section CT obtained at 10-mm incre-
ments versus limited three-level thin-section CT for idiopathic
pulmonary fibrosis: correlation with pathologic scoring. AJR
Am J Roentgenol 1997;169:977e83.
26. Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM,
Grenier PA, et al. Idiopathic interstitial pneumonias: CT
features. Radiology 2005;236:10e21.
1728 W.Y. Chung et al.27. Antoniou KM, Pataka A, Bouros D, Siafakas NM. Pathogenetic
pathways and novel pharmacotherapeutic targets in idiopathic
pulmonary fibrosis. Pulm Pharmacol Ther 2007;20:453e61.
28. Hagimoto N, Kuwano K, Kawasaki M, Yoshimi M, Kaneko Y,
Kunitake R, et al. Induction of interleukin-8 secretion and
apoptosis in bronchiolar epithelial cells by Fas ligation. Am J
Respir Cell Mol Biol 1999;21:436e45.
29. Serrao KL, Fortenberry JD, Owens ML, Harris FL, Brown LA.
Neutrophils induce apoptosis of lung epithelial cells via release
of soluble Fas ligand. Am J Physiol Lung Cell Mol Physiol 2001;
280:L298eL305.
30. Matute-Bello G, Winn RK, Jonas M, Chi EY, Martin TR, Liles WC.
Fas (CD95) induces alveolar epithelial cell apoptosis in vivo:
implications for acute pulmonary inflammation. Am J Pathol
2001;158:153e61.31. O’Sullivan MP, Tyner JW, Holtzman MJ. Apoptosis in the
airways: another balancing act in the epithelial program. Am J
Respir Cell Mol Biol 2003;29:3e7.
32. Kuwano K, Hagimoto N, Maeyama T, Fujita M, Yoshimi M,
Inoshima I, et al. Mitochondria-mediated apoptosis of lung
epithelial cells in idiopathic interstitial pneumonias. Lab Invest
2002;82:1695e706.
33. Lappi-Blanco E, Soini Y, Paakko P. Apoptotic activity is
increased in the newly formed fibromyxoid connective tissue in
bronchiolitis obliterans organizing pneumonia. Lung 1999;177:
367e76.
34. Nakashima N, Kuwano K, Maeyama T, Hagimoto N, Yoshimi M,
Hamada N, et al. The p53-Mdm2 association in epithelial cells
in idiopathic pulmonary fibrosis and non-specific interstitial
pneumonia. J Clin Pathol 2005;58:583e9.
